Cargando…

Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study

OBJECTIVE: A prospective, observational, post-marketing surveillance was conducted to assess the safety and effectiveness of temsirolimus in patients with renal cell carcinoma in Japan. METHODS: Patients prescribed temsirolimus for advanced renal cell carcinoma were registered and received temsiroli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugiyama, Shigeru, Sato, Kazuo, Shibasaki, Yoshiyuki, Endo, Yutaka, Uryu, Taku, Toyoshima, Yasuharu, Oya, Mototsugu, Miyanaga, Naoto, Saijo, Nagahiro, Gemma, Akihiko, Akaza, Hideyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401718/ https://www.ncbi.nlm.nih.gov/pubmed/32458996 http://dx.doi.org/10.1093/jjco/hyaa062

Ejemplares similares

A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
por: Akaza, Hideyuki, et al.
Publicado: (2015)

Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Telomerase Is Upregulated in Irreversible Preneoplastic Lesions during Bladder Carcinogenesis in Rats
por: Shimazui, Toru, et al.
Publicado: (2002)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response
por: Yeo, Winnie, et al.
Publicado: (2015)

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
por: Sato, Kazuo, et al.
Publicado: (2018)

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching
por: Onozawa, Mizuki, et al.
Publicado: (2018)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
por: Venugopal, Balaji, et al.
Publicado: (2013)

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model
por: Chang, Hsuen-Wen, et al.
Publicado: (2018)

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center
por: Afshar, Mehran, et al.
Publicado: (2014)

Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?
por: Kirschey, Sebastian, et al.
Publicado: (2012)

Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype
por: Gabriel, Diana, et al.
Publicado: (2016)

Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
por: Kaley, Thomas J., et al.
Publicado: (2020)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma
por: Wang, Li, et al.
Publicado: (2010)

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
por: Verschraegen, Claire F., et al.
Publicado: (2013)

Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus
por: Briggs, Joseph W., et al.
Publicado: (2017)

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
por: Lee, Jii Bum, et al.
Publicado: (2019)

Present Status and Problems on Molecular Targeted Therapy of Cancer
por: Saijo, Nagahiro
Publicado: (2012)

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
por: Saijo, Nagahiro
Publicado: (2013)

Highlights for ESMO 40: celebration review for lifetime achievement awards
por: Saijo, Nagahiro
Publicado: (2016)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
por: Zardavas, Dimitrios, et al.
Publicado: (2011)

MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab
por: Wagenseller, Aubrey G, et al.
Publicado: (2013)

Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer
por: Pulido, Marina, et al.
Publicado: (2018)

A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus
por: Matsuki, Rei, et al.
Publicado: (2017)

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)
por: Belkacemi, Louiza, et al.
Publicado: (2022)

Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions
por: Ushijima, Hiroki, et al.
Publicado: (2015)

Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
por: Yang, S, et al.
Publicado: (2010)

Temsirolimus in overtreated metastatic renal cancer with subsequent use of sunitinib: A case report
por: JURADO, JOSÉ MIGUEL, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4fpkvsere9144fpk6m6v4a4j3m